
ILMN
Illumina Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
108.7528
Open
104.610
VWAP
107.03
Vol
2.05M
Mkt Cap
17.04B
Low
104.534
Amount
219.56M
EV/EBITDA(TTM)
14.05
Total Shares
159.30M
EV
17.31B
EV/OCF(TTM)
17.31
P/S(TTM)
3.84
Illumina, Inc. is engaged in providing sequencing-and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
1.08B
-2.03%
1.178
+36.96%
1.05B
-2.33%
1.077
-5.5%
1.05B
-5.75%
1.011
+180.94%
Estimates Revision
The market is revising Downward the revenue expectations for Illumina, Inc. (ILMN) for FY2025, with the revenue forecasts being adjusted by -1.18% over the past three months. During the same period, the stock price has changed by 38.69%.
Revenue Estimates for FY2025
Revise Downward

-1.18%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward

-4.99%
In Past 3 Month
Stock Price
Go Up

+38.69%
In Past 3 Month
15 Analyst Rating

-1.25% Downside
Wall Street analysts forecast ILMN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ILMN is 106.29 USD with a low forecast of 70.00 USD and a high forecast of 185.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
7 Hold
2 Sell
Moderate Buy

-1.25% Downside
Current: 107.640

Low
70.00
Averages
106.29
High
185.00

-1.25% Downside
Current: 107.640

Low
70.00
Averages
106.29
High
185.00
Scotiabank
Outperform -> Sector Perform
downgrade
$125
2025-07-11
Reason
Scotiabank
Price Target
$125
2025-07-11
downgrade
Outperform -> Sector Perform
Reason
Scotiabank downgraded Illumina to Sector Perform from Outperform with a $125 price target.
Scotiabank
Outperform
to
Sector Perform
downgrade
$164 -> $125
2025-07-11
Reason
Scotiabank
Price Target
$164 -> $125
2025-07-11
downgrade
Outperform
to
Sector Perform
Reason
Scotiabank downgraded Illumina to Sector Perform from Outperform with a price target of $125, down from $164. The firm awaits more clarity around company-specific macro factors before again recommending the shares. Scotiabank models "conservative assumptions" for Illumina in 2026 given the current ban on the company's sequencers in China and its relatively higher exposure to the U.S. academic and government segment.
Citi
Neutral -> Sell
downgrade
$85 -> $80
2025-07-09
Reason
Citi
Price Target
$85 -> $80
2025-07-09
downgrade
Neutral -> Sell
Reason
Citi downgraded Illumina to Sell from Neutral with a price target of $80, down from $85. The firm sees "significant" risk to estimates in the second half of 2025 and 2026 for Illumina. Citi cites funding uncertainty and increasing competitive risk for the downgrade to Sell.
Barclays
Luke Sergott
Underweight
maintain
$77 -> $85
2025-06-24
Reason
Barclays
Luke Sergott
Price Target
$77 -> $85
2025-06-24
maintain
Underweight
Reason
Barclays analyst Luke Sergott raised the firm's price target on Illumina to $85 from $77 and keeps an Underweight rating on the shares as part of a Q2 preview for the life science and diagnostic tools sector. Sentiment on the group is shifting more positive on the notion that many of the unknown headwinds around policy changes, namely National Institutes of Health budgetary cuts and pharma tariffs, are likely to prove less severe than feared, the analyst tells investors in a research note. Barclays still favors businesses exposed to commercial and clinical volumes, mainly bioprocessing and diagnostics.
Canaccord
Kyle Mikson
Hold
maintain
$87 -> $99
2025-06-11
Reason
Canaccord
Kyle Mikson
Price Target
$87 -> $99
2025-06-11
maintain
Hold
Reason
Canaccord analyst Kyle Mikson raised the firm's price target on Illumina to $99 from $87 and keeps a Hold rating on the shares following a podcast session with CEO Jacob Thaysen. Thaysen commented that strong volume growth from clinical customers should help lead to increased revenue growth as pricing headwinds subside, and elaborated that the growth algorithm remains intact, although this will depend on continued adoption of the NovaSeq X, the analyst tells investors in a research note. Illumina appears positioned for improved execution over the medium-term, but Canaccord remains on the sidelines.
Piper Sandler
David Westenberg
Overweight
downgrade
$190 -> $185
2025-05-15
Reason
Piper Sandler
David Westenberg
Price Target
$190 -> $185
2025-05-15
downgrade
Overweight
Reason
Piper Sandler analyst David Westenberg lowered the firm's price target on Illumina to $185 from $190 following quarterly results. The firm keeps an Overweight rating on the shares.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Illumina Inc (ILMN.O) is 23.59, compared to its 5-year average forward P/E of 83.75. For a more detailed relative valuation and DCF analysis to assess Illumina Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued
5Y Average PE
83.75
Current PE
23.59
Overvalued PE
133.69
Undervalued PE
33.80
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued
5Y Average EV/EBITDA
42.50
Current EV/EBITDA
15.77
Overvalued EV/EBITDA
62.41
Undervalued EV/EBITDA
22.59
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued
5Y Average PS
8.20
Current PS
3.81
Overvalued PS
12.36
Undervalued PS
4.05
Financials
Annual
Quarterly
FY2025Q1
YoY :
-3.25%
1.04B
Total Revenue
FY2025Q1
YoY :
-360.00%
195.00M
Operating Profit
FY2025Q1
YoY :
-203.97%
131.00M
Net Income after Tax
FY2025Q1
YoY :
-203.80%
0.82
EPS - Diluted
FY2025Q1
YoY :
+407.32%
208.00M
Free Cash Flow
FY2025Q1
YoY :
+5.84%
65.61
Gross Profit Margin - %
FY2025Q1
YoY :
+147.85%
20.20
FCF Margin - %
FY2025Q1
YoY :
-207.43%
12.58
Net Margin - %
FY2025Q1
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
784.9K
Volume
6
6-9
Months
1.8M
Volume
14
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
11
4.9M
Volume
Months
6-9
12
2.9M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
65.0K
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
3
24.0K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
ILMN News & Events
Events Timeline
2025-06-25 (ET)
2025-06-25
15:11:26
NIH directs staff not to end any extra research projects for now, NY Times says


2025-06-23 (ET)
2025-06-23
07:18:13
Illumina to acquire SomaLogic for $350M in cash

2025-06-23
07:08:25
Standard BioTools to sell SomaLogic to Illumina for $350M upfront payment

Sign Up For More Events
Sign Up For More Events
News
3.0
07-23NASDAQ.COMShould You Buy or Sell Boston Scientific Stock Ahead of Its Upcoming Earnings?
5.0
07-23TipRanksILMN, NVDA: Cathie Wood Pours Over 5 Million Into Biotech and AI Stocks, Cuts RKLB Stake Again
4.5
07-22NASDAQ.COMTuesday's ETF with Unusual Volume: LSGR
Sign Up For More News
People Also Watch

DRI
Darden Restaurants Inc
202.800
USD
-2.74%

PKG
Packaging Corp of America
205.930
USD
-0.19%

ERIE
Erie Indemnity Co
366.940
USD
+0.43%

VOD
Vodafone Group PLC
11.520
USD
+1.95%

NTRS
Northern Trust Corp
128.760
USD
+3.65%

PSTG
Pure Storage Inc
56.960
USD
-0.63%

TOST
Toast Inc
48.070
USD
+1.35%

CNP
CenterPoint Energy Inc
37.840
USD
+1.94%

ES
Eversource Energy
66.410
USD
+0.06%

NRG
NRG Energy Inc
157.970
USD
-1.61%
FAQ

What is Illumina Inc (ILMN) stock price today?
The current price of ILMN is 107.64 USD — it has increased 2.9 % in the last trading day.

What is Illumina Inc (ILMN)'s business?

What is the price predicton of ILMN Stock?

What is Illumina Inc (ILMN)'s revenue for the last quarter?

What is Illumina Inc (ILMN)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Illumina Inc (ILMN)'s fundamentals?

How many employees does Illumina Inc (ILMN). have?
